Table I.
Targets of miR-126 in lung cancer tumorigenesis.
| Experimental setting | Regulation of miR-126 | Targets | Effects | (Refs.) |
|---|---|---|---|---|
| In vitro, A549 cells | Overexpression knockdown | STAT3 | Proliferation, migration, cell cycle entry, apoptosis susceptibility | (16) |
| In vitro, H1299 cells | Inhibitor, constructed by Vipotion Co., Ltd. | VEGF-A/VEGFR-2/ERK | Proapoptosis, antimetastasis | (17) |
| In vitro, H69AR cells | Overexpression | PI3K/AKT/mTOR | Growth of NSCLC cells | (18) |
| In vitro, H69AR cells | Overexpression | VCAM-1 | Growth of NSCLC cells | (18) |
| In vitro, A549 cells | Overexpression | Hub genes (VEGFA, AKT1 and KRAS) | Invasion of NSCLC cells | (19) |
| In vitro, A549, H1975, H1299 and HCC827 cells In vivo, mice | Overexpression | CCR1 | Growth, migration and invasion of NSCLC cells Reduced tumor growth | (20) |
| In vitro, A549, H1975, H1299, H460 and SPC-A1 cells | Inhibitor, constructed by Shanghai Genepharma Co. Ltd. | SLC7A5 | Angiogenesis, growth, migration and invasion of NSCLC cells | (21) |
| In vitro, SPC-A1, LLC cells In vivo, mice | Overexpression | PI3K/AKT/Snail | EMT The weight of the Lewis lung carcinoma-derived primary tumors increased | (27) |
| In vitro, A549 cells | Overexpression inhibitor, not mentioned | PTEN/PI3K/AKT | Migration and invasion of NSCLC cells | (10) |
| In vitro, 4T1-M cells In vivo, mice | Overexpression | SDF-1α | Recruitment of mesenchymal stem cells Reduced tumor growth | (29) |
| In vitro, A549 cells In vivo, mice | Overexpression | EGFL7, IRS-1 | Angiogenesis Inhibited tumor initiation | (40) |
| In vitro, A549, H1703, H226, H358, HMVEC, NHBE and DMS53 cells In vivo, mice | Overexpression | Crk | Angiogenesis, growth, migration and invasion of NSCLC cells Inhibited tumor initiation | (40,22) |
| In vitro, endothelial cells In vivo, zebrafish | Knockdown | Spred1/MAPK/VEGF p3kr2/PI3K/VEGF | Angiogenesis Loss of vascular integrity and hemorrhage during embryonic development | (50) |
EGFL7, epidermal growth factor-like domain-containing gene 7; SLC7A5, solute carrier family 7 (cationic amino acid transporter, y+ system), member 5; NSCLC, non-small cell lung cancer; IRS-1, insulin receptor substrate 1; Crk, v-crk sarcoma virus CT10 oncogene homologue; Spred1, sprouty-related EVH1 domain-containing protein 1; MAPK, MAP kinase; VEGF, vascular endothelial growth factor; p3kr2, gene p3kr2; PI3K, phosphatidylinositol-3 protein kinase; STAT3, signal transducer and activator of transcription 3; VEGF-A, vascular endothelial growth factor A; ERK, extracellular protein kinase; AKT, protein kinase B; mTOR, mechanistic target of rapamycin; VCAM-1, vascular cell adhesion molecule 1; VEGFA, vascular endothelial growth factor A; AKT1, protein kinase B1; KRAS, Kirsten rat sarcoma viral oncogene homologue; CCR1, chemokine (C-C motif) receptor 1; EMT, epithelial-mesenchymal transition; PTEN, phosphatase and tensin homolog; SDF-1α, stromal cell-derived factor-1α; GRM8, glutamate receptor metabotropic 8; DACH1, dachshund family transcription factor 1; miR, microRNA.